Amgen to buy Celgene ’s Otezla for $13.4B

Amgen has agreed to buy Celgene ’s psoriasis treatment for $13.4 billion in cash, in a deal that will pave the way for Bristol-Myers Squibb to complete its acquisition of Celgene.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news